EXPANDING ACCESS TO HEALTHCARE - novartis.com

EXPANDING ACCESS TO HEALTHCARE ... the Novartis MDT drug donation until 2020. ... program has launched in India, Indonesia, Tanzania, Nepal, provide free multidrug ...

  Access, Free, India, Healthcare, 2200, Expanding, Expanding access to healthcare, Novartis

Corporate governance - Novartis

Corporate governance Contents Letter from the Chairman 82 ... In 2017, we also accelerated our corporate culture change. The Executive Committee took action to …

  Governance, Corporate, Executive, Corporate governance, Novartis

Novartis Annual Report 2017

CHAIRMAN’S LETTER Novartis Annual Report 2017 | 3 ... the World” list in 2017, and we moved to fourth in the 2017 Dow Jones Sustainability Index World, up from seventh ... next-generation antimalarial compound with the poten - tial to treat drug- resistant strains of the malaria parasite. We also made progress in our efforts to expand ...

  Annual, Report, 2017, Drug, World, Novartis, Novartis annual report 2017

Novartis FINANCIAL RESULTS Q4 2018

3/11 Innovative Medicines net sales were USD 9.0 billion (+5%, +9% cc) in the fourth quarter, as Pharmaceuticals BU grew 8% (cc) driven by Cosentyx and Entresto, and Oncology BU grew 11% (cc), driven by AAA including Lutathera, Promacta/Revolade and Tafinlar + Mekinist.Volume contributed 11 percentage points to sales growth.

  Percentages

Sep 18 2018 GIC 100.V4 - Novartis

Principles and Rules Generally, Novartis does not make political contributions. However, since public policy issues impact Novartis business, its employees, and the communities in which Novartis operates, in

  Political, Novartis

Novartis Annual Report 2020

outlined in this report. Delivering on our strategy supported our financial per-formance in 2020. Although the pandemic affected demand in some therapeutic areas, strength in key prod - ucts helped us post net sales of USD 48.7 billion, up 3%, measured in constant currencies (cc). Our core operat-ing income rose 13% (cc) to USD 15.4 billion.

  Annual, Report, 2200, Novartis, Novartis annual report 2020

Q3 2021 Results - novartis.com

§Europe +2%(56% of sales) Bio, Retail, gaining market share §ROW +6% (26% of sales) Steady growth across regions, Biosimilars and Retail §US -20% (18% of sales) Price erosion, contract terminations Q3 Core OpInc0.6bn (-15%) §Unfavorable gross margin in US 1 GROWTH

  Europe, Novartis

Q4 2020 Results - Novartis

- Renewed listing: Tasigna ®, Votrient , Sandostatin® LAR, Zykadia® Rich pipeline: - 2020 NDA approvals: Cosentyx ®AS, Mayzent , Pataday®, Tafinlar®+Mekinist® adj, Zykadia ® 1L - 7 approvals expected in 2021 (NDA submitted in 2020) - Kesimpta® granted China priority review, TQJ230 obtained 1st BTD

  Novartis, Votrient

Novartis COVID-19 Good Practice Guidance for Third Parties

Compliance with Novartis Third Party Code Suppliers must continue to comply with the Novartis Third Party Code (NTPC) during the COVID-19 pandemic. Where fulfilment of contractual obligations to Novartis (e.g. demand for increased delivery of product, shortened deadlines, etc.) puts compliance with the NTPC at risk

  Good, Practices, Guidance, Party, Third, Parties, Novartis, Covid, Novartis covid 19 good practice guidance for third parties, Novartis third party

Third Party Code - Novartis

The Third Party Code is aligned with the Novartis Code of Ethics which is binding for all ... of their identity papers or academic certificates t o secure employment, unless required to do so by local law. If this is the case, workers have access to their papers at all times.

  Certificate, Party, Third, Third party, Novartis

DATA ANALYSIS, INTERPRETATION AND PRESENTATION

analysis to use on a set of data and the relevant forms of pictorial presentation or data display. The decision is based on the scale of measurement of the data. These scales are nominal, ordinal and numerical. Nominal scale A nominal scale is where: the data can be classified into a non-numerical or named categories, and

  Data, Presentation, Of data

Presentation Data Exclusivity Market Protection

Data exclusivity and Market Protection Data exclusivity = Period of time during which an applicant cannot rely on the data in support of another marketing authorisation for the purposes of submitting an application, obtaining marketing authorisation or placing the product on the market, i.e.: generics, hybrids, biosimilars

  Data, Presentation, Data presentation

COVID-19 vaccine safety update - Centers for Disease ...

Summary of v-safe data Pfizer-BioNTech Moderna All COVID-19 vaccines People receiving 1 or more doses in the United States * 12,153,536 9,689,497 21,843,033 Registrants completing at least 1 v-safe health check-in † 997,042 1,083,174 2,080,216 Pregnancies reported to v-safe 8,633 6,498 15,131 * COVID Data Tracker data as of 1/24/2021 †

  Data

Thesis Defense Presentations Outline STUDENT

Title: Microsoft Word - Thesis Defense Presentations_Outline_STUDENT.docx Created Date: 3/2/2015 3:40:32 PM

COVID-19 Vaccines in Adults: Benefit-Risk Discussion

Jul 22, 2021 · severity data (through June 19. th) • VE for hospitalization (95%) • VE for COVID-19 symptomatic cases (95%) • 120-y periodda. Potential harms Estimated cases of . myocarditis. per 1 million second doses of mRNA COVID-19 vaccine, by age/sex using data from VAERS through June 30, 2021. Methods for assessment of benefit-risk balance –

  Data